Rajesh Chopra
Institute of Cancer Research
152 Papers
1.1K Citations
Rajesh Chopra is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Cereblon & Lenalidomide. The author has an hindex of 46, co-authored 147 publications. Previous affiliations of Rajesh Chopra include Imperial College London & University of Oxford.
Chat about Author
Papers
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial
Dc Linch,D. A. Winfield,Ah Goldstone,D. Moir,Barry W. Hancock,A. McMillan,Rajesh Chopra,Donald Milligan,GV Hudson +8 more
TL;DR: A randomised comparison of high-dose chemotherapy plus ABMT with the same drugs at lower doses not requiring bone-marrow rescue in patients with active Hodgkin's disease found that high doses facilitated by ABMT can lead to better disease-free survival.
1K
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding,Susan M. Richards,Rajesh Chopra,Hillard M. Lazarus,Mark R. Litzow,Georgina Buck,I. Jill Durrant,Selina M. Luger,David I. Marks,Ian M. Franklin,Andrew McMillan,Martin S. Tallman,Jacob M. Rowe,Anthony H. Goldstone +13 more
TL;DR: It is concluded from a large, unselected series with mature follow-up that most adults with recurring ALL cannot be rescued using currently available therapies and prevention of recurrence is the best strategy for long-term survival in this disease.
830
Challenges to curing primary brain tumours
Kenneth Aldape,Kevin M. Brindle,Louis Chesler,Rajesh Chopra,Amar Gajjar,Mark R. Gilbert,Nicholas G. Gottardo,David H. Gutmann,Darren Hargrave,Eric C. Holland,David T.W. Jones,Johanna A. Joyce,Pamela Kearns,Mark W. Kieran,Ingo K. Mellinghoff,Melinda S. Merchant,Stefan M. Pfister,Steven M. Pollard,Vijay Ramaswamy,Jeremy N. Rich,Giles W. Robinson,David H. Rowitch,John H. Sampson,Michael D. Taylor,Paul Workman,Richard J. Gilbertson +25 more
TL;DR: An international panel of clinicians and laboratory-based scientists convened by Cancer Research UK identify and discuss seven challenges that must be overcome if the authors are to cure all patients with a brain tumour.
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Jan Krönke,Emma C. Fink,Emma C. Fink,Paul W. Hollenbach,Kyle J. MacBeth,Slater N. Hurst,Namrata D. Udeshi,Philip P Chamberlain,D. R. Mani,Hon-Wah Man,Anita Gandhi,Tanya Svinkina,Rebekka K. Schneider,Marie McConkey,Marcus Järås,Elizabeth A. Griffiths,Meir Wetzler,Lars Bullinger,Brian E. Cathers,Steven A. Carr,Rajesh Chopra,Benjamin L. Ebert,Benjamin L. Ebert +22 more
TL;DR: It is demonstrated that lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1α) by the E3 ubiquitin ligase CUL4–RBX1–DDB1–CRBN (known as CRL4CRBN), resulting in CK1α degradation.
740
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Anita Gandhi,Jian Kang,Courtney G. Havens,Thomas Conklin,Yuhong Ning,Lei Wu,Takumi Ito,Hideki Ando,Michelle Waldman,Anjan Thakurta,Anke Klippel,Hiroshi Handa,Thomas O. Daniel,Peter H. Schafer,Rajesh Chopra +14 more
TL;DR: This work presents a molecular model in which drug binding to cereblon results in the interaction of Ikaros and Aiolos to CRL4CRBN, leading to their ubiquitination, subsequent proteasomal degradation and T cell activation.
580